Robert J. Hariri net worth and biography

Robert Hariri Biography and Net Worth

Director of CryoPort

Dr. Hariri, M.D., Ph.D. became a member of our board of directors in September 2015 and serves as Chairman of the Scientific and Technology Committee and member of the Nomination and Governance Committee of our board of directors. Dr. Hariri is a visionary surgeon, scientist, aviator and entrepreneur and serves the Founder, Chairman and CEO of Cellularity, one of the world’s largest human cellular therapeutics companies. Previously, he served as the CEO of the Cellular Therapeutics Division of Celgene Corporation. Prior to joining Celgene Cellular Therapeutics as president in 2002, Dr. Hariri was founder, chairman and chief scientific officer at Anthrogenesis Corporation/LIFEBANK, Inc., a privately held biomedical technology and service corporation involved in the area of human stem cell therapeutics, which was acquired by Celgene in 2002. Dr. Hariri is also co-founder and president of Human Longevity, Inc., a genomics and cell-therapy company. He also serves on the board of directors of Bio Vie Inc. , He previously served on the board of directors of Myos Corporation (Nasdaq: MYOS), and Bionik Laboratories Corp (OTCQX: BNKL), and is a former member of the Board of Visitors of the Columbia University School of Engineering & Applied Sciences and the Science &Technology Council of the College of Physicians and Surgeons; as well as a member of the Scientific Advisory Board for the Archon X PRIZE for Genomics, which is awarded by the X Prize Foundation. Dr. Hariri is also a Trustee of the Liberty Science Center. He has pioneered the use of stem cells to treat a range of life-threatening diseases and has over 170 issued and pending patents, has authored over 150 published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the placenta as a member of the team which discovered TNF (tumor necrosis factor). Dr. Hariri received his undergraduate training at the Columbia University School of Engineering and Applied Sciences and was awarded his M.D. and Ph.D. degrees from the Cornell University Medical College. Dr. Hariri received his surgical training at The New York Hospital-Cornell Medical Center where he also co-directed the Aitken Laboratory in Neurosurgery.

What is Robert J. Hariri's net worth?: The estimated net worth of Robert J. Hariri is at least $436.35 thousand as of September 11th, 2025. Dr. Hariri owns 51,275 shares of CryoPort stock worth more than $436,350 as of April 2nd. This net worth evaluation does not reflect any other investments that Dr. Hariri may own. Learn More about Robert J. Hariri's net worth.
How do I contact Robert J. Hariri?: The corporate mailing address for Dr. Hariri and other CryoPort executives is 112 Westwood Place Suite 350, Brentwood TN, 37027. CryoPort can also be reached via phone at (949) 470-2300 and via email at [email protected]. Learn More on Robert J. Hariri's contact information.
Has Robert J. Hariri been buying or selling shares of CryoPort?: Robert J. Hariri has not been actively trading shares of CryoPort during the last quarter. Most recently, Robert J. Hariri sold 25,000 shares of the business's stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $9.71, for a transaction totalling $242,750.00. Following the completion of the sale, the director now directly owns 51,275 shares of the company's stock, valued at $497,880.25. Learn More on Robert J. Hariri's trading history.
Who are CryoPort's active insiders?: CryoPort's insider roster includes Richard Berman (Director), Daniel Hancock (Director), Robert Hariri (Director), Ramkumar Mandalam (Director), Mark Sawicki (Insider), Jerrell Shelton (CEO), Robert Stefanovich (CFO), and Edward Zecchini (Director). Learn More on CryoPort's active insiders.
Are insiders buying or selling shares of CryoPort?: During the last twelve months, insiders at the sold shares 24 times. They sold a total of 601,256 shares worth more than $4,290,346.44. The most recent insider tranaction occured on March, 23rd when CFO Robert Stefanovich sold 1,094 shares worth more than $8,948.92. Insiders at CryoPort own 10.0% of the company. Learn More about insider trades at CryoPort.
Information on this page was last updated on 3/23/2026.

Robert J. Hariri Insider Trading History at CryoPort

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/11/2025	Sell	25,000	$9.71	$242,750.00	51,275
8/22/2025	Sell	5,000	$8.60	$43,000.00	26,275
5/28/2025	Sell	12,500	$6.10	$76,250.00	8,061
11/21/2024	Sell	2,500	$6.48	$16,200.00	20,561
8/19/2024	Sell	1,000	$9.46	$9,460.00	23,061
8/16/2024	Sell	1,000	$9.00	$9,000.00	23,561
8/14/2024	Sell	1,000	$8.40	$8,400.00	24,561
12/14/2023	Sell	800	$16.89	$13,512.00	12,716
12/11/2023	Sell	1,000	$15.50	$15,500.00	13,516
9/6/2023	Sell	1,500	$13.60	$20,400.00	14,516
8/11/2022	Sell	2,000	$43.29	$86,580.00	7,911

Robert J. Hariri Buying and Selling Activity at CryoPort

CryoPort Company Overview

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Today's Range

Now: $8.37

$8.30

$8.46

50 Day Range

MA: $8.61

$7.72

$10.93

2 Week Range

Now: $8.37

$4.63

$11.45

Volume

5,898 shs

Average Volume

387,747 shs

Market Capitalization

$417.48 million

P/E Ratio

6.39

Dividend Yield

N/A

Beta

1.68